|
|
Article: CVRx[R] Enrolls First Patient in HOPE4HF[TM] Clinical Trial.
- Article from:
- Business Wire
- Article date:
- October 1, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Study Evaluates Use of Company's Rheos([R]) Therapy in Treating Heart Failure
MINNEAPOLIS -- CVRx, Inc. reported the first enrollment of a patient in the HOPE4HF Trial, a study that is evaluating the RheosSystem to treat heart failure. The Rheos System uses Baroreflex Activation Therapy([R])technology, an entirely new non-pharmaceutical approach designed to treat cardiovascular disease. The HOPE4HF Trial is being conducted under an approved investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA). Data from this pivotal trial are intended to support a Pre-Market Approval (PMA) application to the FDA for use of the Rheos System in ...